

QUARTERLY ACTIVITIES REPORT AND APPENDIX 4C FOR THE PERIOD ENDED 30 JUNE 2023

ASX:RLG 31 JULY 2023

Q4 FY2023 APPENDIX 4C & KEY FINANCIAL DATA





2

Q4 FY2023 RLG'S BUSINESS FOCUS



CONSUMER HEALTH, WELLBEING & FOOD ONLINE & OFFLINE

- Continued expansion of consumer health, well being and food products & additional sales channels with tactical product & brand selection.
- RLG focussed on development in lucrative high-growth health, wellbeing and food products segments, including own VORA brand.
- RLG was appointed to provide digital marketing, social media operations and e-commerce store operations in both Australia and China to sell the Fiji Kava range
- Binding term sheet executed with AULife International to market and sell Australian products to an established Chinese customer base.
- Expanded customer reach through key partnerships, adding China cross border e-Commerce company AULife sales channels and product range, adding sales of Australian milk powder products and range of dairy food products.
- Strengthened RLG's capacity to benefit from China's large and growing middle class consumers and increasing health awareness.
- Continued reduction in cost base across the group.
- Martin Place Equity Partners engaged to provide public and investor relations services and to introduce Chinese investors to RLG.

HEALTH & WELLBEING EXPANSION CHANNEL EXPANSION, SELLING FIJI KAVA IN CHINA & AUSTRALIA

In Q4 FY2023 RLG was contracted by The Calmer Co (ASX:CCO), a global beverage and natural medicine company, as its distributor for China and Australia.

RLG was appointed to provide digital marketing, social media operations and ecommerce store operations in both Australia and China to sell the Fiji Kava range including relaxant and sleep aid capsules, drinking kava, dietary shots moving into new ready to drink 'RTD' products TakiMai[®] and Leilo[®].

RLG has achieved sales growth month on month by 67% in May and 33% in June with continued strong sales growth in July evident.

The Tmall flagship store is expected to be online by Q2 of FY24 and will commence selling FijiKava® branded products, and other branded products can follow from TakiMai® and Leilo® as the flagship store allows for multiple brands from CCO.

Premarketing via Little Red Book and other Chinese social media channels is underway in China in the lead up to launch of the online sales channels.



通神 没错 但是请不要让...







Q4 FY2023 - BINDING TERMSHEET FOR CHINA SALES WITH FOCUS ON AUSTRALIAN PRODUCT SALES

- Binding term sheet executed with cross border e-Commerce company AULife International to market and sell Australian products to an established Chinese customer base.
- Agreement generated first sales in June 2023, with further sales growth in July.
- AULife holds distribution rights for a leading portfolio of Australian brands and products and materially expands RLG's existing distribution footprint in the Chinese consumer marketplace.
- The key objective of the partnership is to launch a unique ecommerce platform dedicated to the sale and distribution of leading Australian brands into China.
- New channel focussed on high-quality, authentic Australian products range.
- Incentivisation by provision of Performance Rights for delivery of gross profit to RLG and for contribution towards achievement of market capitalisation outcomes.



UNLOCK A WORLD





- RLG announced its partnership with AULife International to jointly sell both RLG's product range and AULife's range of products across the groups' combined sales channels.
- This broadens RLG's reach and access to the market in China for both Australian and International products.
- First new sales of Australian milk powder products achieved in June 2023 in partnership with AULife.

Aulife



- 1. Cross Border eCommerce (online channels)
- 2. General Trade Sales in China (offline channels)
- 3. Chinese Brand Localisation Services
- 4. KOL (Key Opinion Leader) Influencer Marketing
- 5. Comprehensive Range of Marketing Services



POST Q4 FY2023 – OPERATIONAL AND FUNDING HIGHLIGHTS

- On 29 June 2023, RLG executed a binding term sheet with China-focused e-Commerce company AULife International Pty Ltd ("AULife") to partner in marketing and sales initiatives for their respective portfolios of Australian and international products to Chinese consumers and with Martin Place Equity Partners Pty Ltd ("Martin Place") to provide investor relations services and to promote the Company to Chinese investors. Full details are set out in the ASX Announcement, "RLG SIGNS BINDING TERMSHEET FOR CHINA SALES & INVESTOR RELATIONS", released 29 June 2023.
- Post the end of the quarter, on 14 July 2023, RLG entered into agreements to obtain funding of an additional \$600,000 by way of a combination of a Convertible Loan to the value of \$200,000 from existing shareholder, Xiaodan Wu, (a Hong Kong based substantial shareholder in RLG) and \$400,000 in loans from directors, with the funds to be applied to drive immediate growth in sales revenue and gross profit for the Company in this quarter.
- Key terms of the Convertible Loan include 8% p/a interest rate plus 5 RLG shares for every \$1 loaned, with a term of 12 months and right to convert to fully paid shares at \$0.025.
- Key terms of the Director Loans include 10% p/a interest rate on the amount drawn down, payable in arrears.



Q4 FY2023

Corporate, Financial Performance & Other Cash Items

- Product Manufacturing and Operating Costs in the quarter were \$1,569k, down from \$1,865k in the prior quarter
- Payments for staff costs, including directors, in the quarter totalled \$634k down from \$866k in the prior quarter.
- Administration and corporate costs in the quarter were \$204k down from \$217k in the prior quarter.
- Fees paid to Non-Executive Directors were \$30k and fees paid to Executive Directors during the Quarter totalled \$142k.





RLG MULTI-CHANNEL REVENUE MODEL

REVENUE FROM RECURRING SERVICES FEES + PRODUCT SALES













RLG CONNECTS GLOBAL BRANDS WITH CUSTOMERS

- An established, leading e-commerce platform provider
- Selling food, health and well being products
- Global Client Base 7 Countries
- Own Brand VORA "Good for you" Food Products launched
- Market Focus Australia, South East Asia & Emerging Markets
- Targeting growing margin on Product Sales





ASX:RLG BUSINESS OVERVIEW



SELLING FOOD, HEALTH AND WELLBEING PRODUCTS ONLINE AND VIA SALES CHANNELS

- RLG matches consumer demand with brands via multiple channels
- RLG drives online and in-market sales of international brands
- RLG's focus on Health, Wellbeing and Food products including own VORA brand and product range
- Strong China focus the largest e-commerce market globally, generating almost 50% of the world's transactions, valued at \$USD2.3 trillion and providing access to 940 million online shoppers*
- The size of the addressable market and RLG's established and expanding platforms for accessing this market provides a solid foundation to drive toward future growth and profitability





[•] www.trade.gov/country-commercial-guides/china-ecommerce, www.statista.com/statistics/663464/alibaba-cumulative-active-mobile-users-taobao-tmall/

11



Compelling in- demand service:	E-commerce & sales platforms selling food, health and wellbeing products.
Proven platform ready for scale:	Strong international product range from NZ, UK, Europe, USA, South America, Australia.
Infrastructure investment creates turnkey solution:	China team, Australian team, logistics, warehousing, translation, marketing, distribution and e-commerce support for rapid market entry.
Company Owned Health Brand:	VORA – "Good for you" health food range, selling into high demand, high growth markets, delivering margin benefits & ability to rapidly respond to demand.
Multiple Revenue Lines & Channels:	Mix of stable recurring revenues and product sales with growing range of products and sales channels.





UNLOCK A WORLD OF POTENTIAL

ASX:RLG

Twitter\$RLG_InvestorsLinkedInRooLife GroupWebsitewww.roolifegroup.com.au

Issued by: RooLife Group Ltd Authorised by: The Board of RooLife Group Ltd

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

RooLife Group Limited

ABN

14 613 410 398

Quarter ended ("current quarter")

30 June 2023

Con	isolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1.	Cash flows from operating activities		
1.1	Receipts from customers	2,530	12,093
1.2	Payments for		
	(a) research and development	-	-
	(b) product manufacturing and operating costs	(1,569)	(8,646)
	(c) advertising and marketing	(198)	(893)
	(d) leased assets	-	-
	(e) staff costs	(634)	(3,004)
	(f) administration and corporate costs	(204)	(1,002)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	17	25
1.5	Interest and other costs of finance paid	(10)	(28)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	79
1.8	Other (provide details if material)	(39)	(203)
1.9	Net cash from / (used in) operating activities	(107)	(1,579)

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(4)	(14)
	(d) investments	-	-
	(e) intellectual property	-	(58)
	(f) other non-current assets	-	-

Con	solidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	50
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	10	(19)
2.6	Net cash from / (used in) investing activities	6	(41)

3.	Cash flows from financing activities	
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-
3.2	Proceeds from issue of convertible debt securities	-
3.3	Proceeds from exercise of options	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-
3.5	Proceeds from borrowings	-
3.6	Repayment of borrowings	-
3.7	Transaction costs related to loans and borrowings	-
3.8	Dividends paid	-
3.9	Other (provide details if material)	-
3.10	Net cash from / (used in) financing activities	-

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,514	2,416
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(107)	(1,579)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	6	(41)

Con	solidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	600
4.5	Effect of movement in exchange rates on cash held	7	24
4.6	Cash and cash equivalents at end of period	1,420	1,420

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,420	1,514
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,420	1,514

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	182 ¹
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
	f any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include ation for, such payments.	e a description of, and an

¹ Payments totalling \$172,000 were made to directors for fees and superannuation on fees.

Payments totalling \$10,000 were made to Murcia Pestell Hillard Pty Ltd, a company related to Mr. Grant Pestell, for the provision of legal services.

7.	Financing facilities Note: the term "facility' includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	1,000	600
7.2	Credit standby arrangements	50	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	1,050	600
7.5	Unused financing facilities available at qu	arter end	450
 7.6 Include in the box below a description of each facility above, rate, maturity date and whether it is secured or unsecured. If facilities have been entered into or are proposed to be entered 			itional financing
	 include a note providing details of those facilities as well. Working Capital Loan Agreement for a line of credit of \$1,000,000, with Saxby Capital Investments Pty Ltd, to be drawn on a case-by-case basis for each sale of product into China. Interest is calculated at 10% per annum on loan amount drawn down, payable in arrears. Repayment of the drawn down amount of \$600,000 is due on 1 April 2024. The finance facility is secured by a fixed and floating charge over receivables and inventory to the equivalent value of amount outstanding of the Loan. Business Overdraft Facility of \$49,999 with Australia and New Zealand Banking Group Limited (ANZ) at an interest rate of 10.45%. The facility is unsecured and has no fixed maturity date. 		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(107)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,420
8.3	Unused finance facilities available at quarter end (item 7.5)	450
8.4	Total available funding (item 8.2 + item 8.3)	1,870
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	17.48
	Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 figure for the estimated quarters of funding available must be included in item 8.5.	as "N/A". Otherwise, a

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 31 July 2023

Authorised by: The Board of RooLife Group Ltd

Notes

- 1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- 2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- 3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- 4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- 5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.